Some of the best opportunities going forward may be among the worst-performing small-company stocks that have gone public over the last 11 years, advises the chief equity strategist at BTIG. In particular, he is “zeroing in on companies that have a history with private equity or venture capital backers who could look to take advantage by acquiring the company. That would turn around some of that historic poor performance in a hurry.” For 25 struggling small-company stocks he sees as presenting real opportunities, CLICK HERE.
Today’s article highlights a dozen emerging pharmaceutical companies that could potentially have a big year – and identifies the multiple catalysts that 2017 holds for each of them – from financials releases to key clinical trial milestones to potential acquisition. To find out what these 12 emerging pharmaceutical companies are, what the analyst sentiment on them is, and what their respective catalysts this year are (and when they are set to occur), CLICK HERE.
While most of the attention during the presidential campaign was focused on President Trump’s more controversial proposals, a less controversial proposal Trump made on the campaign trail was a tax holiday for untaxed foreign earnings repatriated to the U.S. by American companies – which, if acted on, could free up $1 trillion or more for dividends, share buybacks and acquisitions. So, for investors looking to benefit from this potential flood of cash flowing to U.S. shores, what two sectors likely to account for much of this repatriated money – as well as specific stocks within those sectors – might they want to look at? CLICK HERE to find out.